Current Overview on Hypercoagulability in COVID-19.
Am J Cardiovasc Drugs
; 20(5): 393-403, 2020 Oct.
Article
en En
| MEDLINE
| ID: mdl-32748336
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Trastornos de la Coagulación Sanguínea
/
Infecciones por Coronavirus
/
Quimioprevención
/
Trombofilia
/
Pandemias
/
Fármacos Hematológicos
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article